Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1775 entries
Sorted by: Best Match Show Resources per page
Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels.

Basic research in cardiology

[No authors listed]
PMID: 27519302
Basic Res Cardiol. 2004 May;99(3):239. doi: 10.1007/s00395-004-0464-9.

No abstract available.

Cite
Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol. 2004;99(3):239doi: 10.1007/s00395-004-0464-9.
(2004). Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic research in cardiology, 99(3), 239. https://doi.org/10.1007/s00395-004-0464-9
"Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels." Basic research in cardiology vol. 99,3 (2004): 239. doi: https://doi.org/10.1007/s00395-004-0464-9
Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol. 2004 May;99(3):239. doi: 10.1007/s00395-004-0464-9. PMID: 27519302.
Copy Download .nbib Format: NLM
Bone marrow mesenchymal stem cells transplantation promotes the release of endogenous erythropoietin after ischemic stroke.

Neural regeneration research

Lv W, Li WY, Xu XY, Jiang H, Bang OY.
PMID: 26487854
Neural Regen Res. 2015 Aug;10(8):1265-70. doi: 10.4103/1673-5374.162759.

This study investigated whether bone marrow mesenchymal stem cell (BMSC) transplantation protected ischemic cerebral injury by stimulating endogenous erythropoietin. The model of ischemic stroke was established in rats through transient middle cerebral artery occlusion. Twenty-four hours later, 1 ×...

Cite
Lv W, Li WY, Xu XY, et al. Bone marrow mesenchymal stem cells transplantation promotes the release of endogenous erythropoietin after ischemic stroke. Neural Regen Res. 2015;10(8):1265-70doi: 10.4103/1673-5374.162759.
Lv, W., Li, W. Y., Xu, X. Y., Jiang, H., & Bang, O. Y. (2015). Bone marrow mesenchymal stem cells transplantation promotes the release of endogenous erythropoietin after ischemic stroke. Neural regeneration research, 10(8), 1265-70. https://doi.org/10.4103/1673-5374.162759
Lv, Wen, et al. "Bone marrow mesenchymal stem cells transplantation promotes the release of endogenous erythropoietin after ischemic stroke." Neural regeneration research vol. 10,8 (2015): 1265-70. doi: https://doi.org/10.4103/1673-5374.162759
Lv W, Li WY, Xu XY, Jiang H, Bang OY. Bone marrow mesenchymal stem cells transplantation promotes the release of endogenous erythropoietin after ischemic stroke. Neural Regen Res. 2015 Aug;10(8):1265-70. doi: 10.4103/1673-5374.162759. PMID: 26487854; PMCID: PMC4590239.
Copy Download .nbib Format: NLM
Idiopathic erythrocytosis in a patient on chronic hemodialysis.

Kidney research and clinical practice

Lee DH, Min JH, Bae SB, Gil HW, Yang JO, Lee EY, Hong SY.
PMID: 26484022
Kidney Res Clin Pract. 2015 Mar;34(1):60-3. doi: 10.1016/j.krcp.2014.09.004. Epub 2014 Nov 27.

A 78-year-old man on hemodialysis presented to our hospital with erythrocytosis. He had started hemodialysis 4 years previously, with a hemoglobin level of 9.8 g/dL, and was administered erythropoiesis stimulating agents and ferrous sulfate. Two years previously, his hemoglobin...

Cite
Lee DH, Min JH, Bae SB, et al. Idiopathic erythrocytosis in a patient on chronic hemodialysis. Kidney Res Clin Pract. 2014;34(1):60-3doi: 10.1016/j.krcp.2014.09.004.
Lee, D. H., Min, J. H., Bae, S. B., Gil, H. W., Yang, J. O., Lee, E. Y., & Hong, S. Y. (2015). Idiopathic erythrocytosis in a patient on chronic hemodialysis. Kidney research and clinical practice, 34(1), 60-3. https://doi.org/10.1016/j.krcp.2014.09.004
Lee, Dong Hyun, et al. "Idiopathic erythrocytosis in a patient on chronic hemodialysis." Kidney research and clinical practice vol. 34,1 (2015): 60-3. doi: https://doi.org/10.1016/j.krcp.2014.09.004
Lee DH, Min JH, Bae SB, Gil HW, Yang JO, Lee EY, Hong SY. Idiopathic erythrocytosis in a patient on chronic hemodialysis. Kidney Res Clin Pract. 2015 Mar;34(1):60-3. doi: 10.1016/j.krcp.2014.09.004. Epub 2014 Nov 27. PMID: 26484022; PMCID: PMC4570647.
Copy Download .nbib Format: NLM
Exogenous erythropoietin aggravates retinal neovascularizationin a murine model of proliferative retinopathy.

Turkish journal of medical sciences

Yang N, Zhang W, He T, Xing Y.
PMID: 29152948
Turk J Med Sci. 2017 Nov 13;47(5):1642-1650. doi: 10.3906/sag-1609-49.

Background/aim: Erythropoietin (EPO) has been proven recently to be a critical mediator in retinal neovascularization (RNV). Previous studies have indicated that the use of recombinant human EPO (rEPO) is a high risk factor in the development of retinopathy of...

Cite
Yang N, Zhang W, He T, et al. Exogenous erythropoietin aggravates retinal neovascularizationin a murine model of proliferative retinopathy. Turk J Med Sci. 2017;47(5):1642-1650doi: 10.3906/sag-1609-49.
Yang, N., Zhang, W., He, T., & Xing, Y. (2017). Exogenous erythropoietin aggravates retinal neovascularizationin a murine model of proliferative retinopathy. Turkish journal of medical sciences, 47(5), 1642-1650. https://doi.org/10.3906/sag-1609-49
Yang, Ning, et al. "Exogenous erythropoietin aggravates retinal neovascularizationin a murine model of proliferative retinopathy." Turkish journal of medical sciences vol. 47,5 (2017): 1642-1650. doi: https://doi.org/10.3906/sag-1609-49
Yang N, Zhang W, He T, Xing Y. Exogenous erythropoietin aggravates retinal neovascularizationin a murine model of proliferative retinopathy. Turk J Med Sci. 2017 Nov 13;47(5):1642-1650. doi: 10.3906/sag-1609-49. PMID: 29152948.
Copy Download .nbib Format: NLM
Physiology and pharmacology of erythropoietin.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Jelkmann W.
PMID: 24273483
Transfus Med Hemother. 2013 Oct;40(5):302-9. doi: 10.1159/000356193. Epub 2013 Jul 19.

Human erythropoietin (Epo) is a 30.4 kDa glycoprotein hormone composed of a single 165 amino acid residues chain to which four glycans are attached. The kidneys are the primary sources of Epo, its synthesis is controlled by hypoxia-inducible transcription...

Cite
Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013;40(5):302-9doi: 10.1159/000356193.
Jelkmann, W. (2013). Physiology and pharmacology of erythropoietin. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 40(5), 302-9. https://doi.org/10.1159/000356193
Jelkmann, Wolfgang. "Physiology and pharmacology of erythropoietin." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 40,5 (2013): 302-9. doi: https://doi.org/10.1159/000356193
Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013 Oct;40(5):302-9. doi: 10.1159/000356193. Epub 2013 Jul 19. PMID: 24273483; PMCID: PMC3822280.
Copy Download .nbib Format: NLM
The relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients.

Nephro-urology monthly

Afsar B.
PMID: 24282790
Nephrourol Mon. 2013 Jul 01;5(3):806-12. doi: 10.5812/numonthly.8919. Epub 2013 May 28.

BACKGROUND: Seroconversion following Hepatitis B virus (HBV) vaccine in hemodialysis (HD) patients has been shown to be suboptimal. Nutritional and immunological factors were shown to influence the seroconversion related to HBV vaccination in HD patients. Resistance to erythropoiesis stimulating...

Cite
Afsar B. The relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients. Nephrourol Mon. 2013;5(3):806-12doi: 10.5812/numonthly.8919.
Afsar, B. (2013). The relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients. Nephro-urology monthly, 5(3), 806-12. https://doi.org/10.5812/numonthly.8919
Afsar, Baris. "The relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients." Nephro-urology monthly vol. 5,3 (2013): 806-12. doi: https://doi.org/10.5812/numonthly.8919
Afsar B. The relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients. Nephrourol Mon. 2013 Jul 01;5(3):806-12. doi: 10.5812/numonthly.8919. Epub 2013 May 28. PMID: 24282790; PMCID: PMC3830906.
Copy Download .nbib Format: NLM
Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population.

Journal of biomedical research

Zhang C, Li Z, Cao Q, Qin C, Cai H, Zhou H, Qian J, Tao L, Ju X, Yin C.
PMID: 25469114
J Biomed Res. 2014 Nov;28(6):456-61. doi: 10.7555/JBR.28.20130126. Epub 2014 Aug 11.

Erythropoietin (EPO) is a circulating glycosylated protein hormone and has been implicated in the development and progression of non-hematopoietic tissue tumors. The objective of the present study was to determine if the EPO rs576236 polymorphism was associated with the...

Cite
Zhang C, Li Z, Cao Q, et al. Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population. J Biomed Res. 2014;28(6):456-61doi: 10.7555/JBR.28.20130126.
Zhang, C., Li, Z., Cao, Q., Qin, C., Cai, H., Zhou, H., Qian, J., Tao, L., Ju, X., & Yin, C. (2014). Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population. Journal of biomedical research, 28(6), 456-61. https://doi.org/10.7555/JBR.28.20130126
Zhang, Chao, et al. "Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population." Journal of biomedical research vol. 28,6 (2014): 456-61. doi: https://doi.org/10.7555/JBR.28.20130126
Zhang C, Li Z, Cao Q, Qin C, Cai H, Zhou H, Qian J, Tao L, Ju X, Yin C. Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population. J Biomed Res. 2014 Nov;28(6):456-61. doi: 10.7555/JBR.28.20130126. Epub 2014 Aug 11. PMID: 25469114; PMCID: PMC4250524.
Copy Download .nbib Format: NLM
Decreased stability of erythroblastic islands in integrin β3-deficient mice.

Physiological reports

Wang Z, Vogel O, Kuhn G, Gassmann M, Vogel J.
PMID: 24303107
Physiol Rep. 2013 Jul;1(2):e00018. doi: 10.1002/phy2.18. Epub 2013 Jun 28.

Erythroblasts proliferate and differentiate in hematopoietic organs within erythroblastic islands (EI) composed of erythropoietic progenitor cells attached to a central macrophage. This cellular interaction crucially involves the erythroid intercellular adhesion molecule-4 (ICAM-4) and αv integrin. Because integrins are biologically...

Cite
Wang Z, Vogel O, Kuhn G, et al. Decreased stability of erythroblastic islands in integrin β3-deficient mice. Physiol Rep. 2013;1(2):e00018doi: 10.1002/phy2.18.
Wang, Z., Vogel, O., Kuhn, G., Gassmann, M., & Vogel, J. (2013). Decreased stability of erythroblastic islands in integrin β3-deficient mice. Physiological reports, 1(2), e00018. https://doi.org/10.1002/phy2.18
Wang, Zhenghui, et al. "Decreased stability of erythroblastic islands in integrin β3-deficient mice." Physiological reports vol. 1,2 (2013): e00018. doi: https://doi.org/10.1002/phy2.18
Wang Z, Vogel O, Kuhn G, Gassmann M, Vogel J. Decreased stability of erythroblastic islands in integrin β3-deficient mice. Physiol Rep. 2013 Jul;1(2):e00018. doi: 10.1002/phy2.18. Epub 2013 Jun 28. PMID: 24303107; PMCID: PMC3831914.
Copy Download .nbib Format: NLM
Human fetal liver cells for regulated ex vivo erythropoietin gene therapy.

Molecular therapy. Methods & clinical development

El Filali E, Duijst S, Hiralall JK, Legrand N, van Gulik T, Hoekstra R, Seppen J.
PMID: 26015950
Mol Ther Methods Clin Dev. 2014 Mar 12;1:14003. doi: 10.1038/mtm.2014.3. eCollection 2014.

Possible risks and lack of donor livers limit application of liver transplantation. Liver cell transplantation is, at this moment, not a feasible alternative because engraftment in the liver is poor. Furthermore, there is also shortage of cells suitable for...

Cite
El Filali E, Duijst S, Hiralall JK, et al. Human fetal liver cells for regulated ex vivo erythropoietin gene therapy. Mol Ther Methods Clin Dev. 2014;1:14003doi: 10.1038/mtm.2014.3.
El Filali, E., Duijst, S., Hiralall, J. K., Legrand, N., van Gulik, T., Hoekstra, R., & Seppen, J. (2014). Human fetal liver cells for regulated ex vivo erythropoietin gene therapy. Molecular therapy. Methods & clinical development, 114003. https://doi.org/10.1038/mtm.2014.3
El Filali, Ebtisam, et al. "Human fetal liver cells for regulated ex vivo erythropoietin gene therapy." Molecular therapy. Methods & clinical development vol. 1 (2014): 14003. doi: https://doi.org/10.1038/mtm.2014.3
El Filali E, Duijst S, Hiralall JK, Legrand N, van Gulik T, Hoekstra R, Seppen J. Human fetal liver cells for regulated ex vivo erythropoietin gene therapy. Mol Ther Methods Clin Dev. 2014 Mar 12;1:14003. doi: 10.1038/mtm.2014.3. eCollection 2014. PMID: 26015950; PMCID: PMC4362349.
Copy Download .nbib Format: NLM
Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.

American health & drug benefits

Powers A, Faria C, Broder MS, Chang E, Cherepanov D.
PMID: 24991341
Am Health Drug Benefits. 2012 Nov;5(7):455-65.

BACKGROUND: Myelodysplastic syndrome (MDS) is rare in people aged

Cite
Powers A, Faria C, Broder MS, et al. Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. Am Health Drug Benefits. 2012;5(7):455-65
Powers, A., Faria, C., Broder, M. S., Chang, E., & Cherepanov, D. (2012). Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. American health & drug benefits, 5(7), 455-65.
Powers, Annette, et al. "Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care." American health & drug benefits vol. 5,7 (2012): 455-65.
Powers A, Faria C, Broder MS, Chang E, Cherepanov D. Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. Am Health Drug Benefits. 2012 Nov;5(7):455-65. PMID: 24991341; PMCID: PMC4031699.
Copy Download .nbib Format: NLM
Comment on: Protective Role of Recombinant Human Erythropoietin in Kidney and Lung Injury Following Renal Bilateral Ischemia-reperfusion in Rat Model.

International journal of preventive medicine

Ardalan MR, Nasri H, Rafieian-Kopaei M.
PMID: 24319567
Int J Prev Med. 2013 Oct;4(10):1226-7.

No abstract available.

Cite
Ardalan MR, Nasri H, Rafieian-Kopaei M. Comment on: Protective Role of Recombinant Human Erythropoietin in Kidney and Lung Injury Following Renal Bilateral Ischemia-reperfusion in Rat Model. Int J Prev Med. 2013;4(10):1226-7
Ardalan, M. R., Nasri, H., & Rafieian-Kopaei, M. (2013). Comment on: Protective Role of Recombinant Human Erythropoietin in Kidney and Lung Injury Following Renal Bilateral Ischemia-reperfusion in Rat Model. International journal of preventive medicine, 4(10), 1226-7.
Ardalan, Mohammad-Reza, et al. "Comment on: Protective Role of Recombinant Human Erythropoietin in Kidney and Lung Injury Following Renal Bilateral Ischemia-reperfusion in Rat Model." International journal of preventive medicine vol. 4,10 (2013): 1226-7.
Ardalan MR, Nasri H, Rafieian-Kopaei M. Comment on: Protective Role of Recombinant Human Erythropoietin in Kidney and Lung Injury Following Renal Bilateral Ischemia-reperfusion in Rat Model. Int J Prev Med. 2013 Oct;4(10):1226-7. PMID: 24319567; PMCID: PMC3843314.
Copy Download .nbib Format: NLM
The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial.

Redox report : communications in free radical research

Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, On Behalf Of The Hero Study Collaborative Group.
PMID: 26083328
Redox Rep. 2016 Jan;21(1):14-23. doi: 10.1179/1351000215Y.0000000022. Epub 2016 Mar 04.

OBJECTIVE: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on...

Cite
Zhang L, Coombes J, Pascoe EM, et al. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep. 2016;21(1):14-23doi: 10.1179/1351000215Y.0000000022.
Zhang, L., Coombes, J., Pascoe, E. M., Badve, S. V., Dalziel, K., Cass, A., Clarke, P., Ferrari, P., McDonald, S. P., Morrish, A. T., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, L. A., Hawley, C. M., Johnson, D. W., & On Behalf Of The Hero Study Collaborative Group. (2016). The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox report : communications in free radical research, 21(1), 14-23. https://doi.org/10.1179/1351000215Y.0000000022
Zhang, Lei, et al. "The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial." Redox report : communications in free radical research vol. 21,1 (2016): 14-23. doi: https://doi.org/10.1179/1351000215Y.0000000022
Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, On Behalf Of The Hero Study Collaborative Group. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep. 2016 Jan;21(1):14-23. doi: 10.1179/1351000215Y.0000000022. Epub 2016 Mar 04. PMID: 26083328; PMCID: PMC6837737.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1775 entries